| Ketamine for Treatment-Resistant Bipolar Disorder (NCT05004896) | Joshua Rosenblat | 2022-07-04 |
| Children's Bipolar Network Treatment Trial I (NCT05427123) | University of California, Los Angeles | 2022-07-01 |
| Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (NCT05303064) | Alkermes, Inc. | 2022-06-30 |
| Evaluating the Hypothesized Mechanism of Action of N-acetylcysteine for Bipolar Disorder (NCT05340504) | Medical University of South Carolina | 2022-05-13 |
| Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders (NCT05064319) | Medical University of South Carolina | 2022-02-24 |
| Obsessions and Suicidality in Youth With Bipolar 1 Disorder (NCT05878808) | Cairo University | 2022-02-01 |
| Aripiprazole Once-Monthly in Hospitalized Patients (INITIATE) (NCT04907279) | Otsuka Canada Pharmaceutical Inc. | 2021-11-01 |
| The Effect of Interpersonal Relationships and Social Rhythm Therapy Individuals With Bipolar Disorder (NCT05420792) | Ege University | 2021-08-01 |
| Assessing the Role of Cariprazine in Improving Cognition in Euthymic Bipolar Patients (NCT04771299) | Lakshmi N Yatham | 2021-07-07 |
| Naturalistic Study of Ketamine in the Treatment of Depression (NCT05249309) | Hospital de Clinicas de Porto Alegre | 2021-05-01 |
| A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. (NCT04777357) | AbbVie | 2021-04-28 |
| Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder (NCT04819776) | Vanda Pharmaceuticals | 2021-03-22 |
| Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder (NCT04578756) | AbbVie | 2021-02-01 |
| Emotional Proactive Processing in Bipolar Disorder (NCT04561622) | University Hospital, Grenoble | 2020-10-01 |
| Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients (NCT04315792) | Jina Pharmaceuticals Inc. | 2020-08-03 |
| A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Bipolar Disorder (NCT04211428) | ProgenaBiome | 2020-03-02 |
| Optimizing Response to Li Treatment Through Personalized Evaluation of Individuals With Bipolar I Disorder: The R-LiNK Initiative (NCT04209140) | Assistance Publique - Hôpitaux de Paris | 2020-01-10 |
| Early Psychosis Intervention - Spreading Evidence-based Treatment (NCT03919760) | Centre for Addiction and Mental Health | 2020-01-03 |
| Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia (NCT04127058) | Vanda Pharmaceuticals | 2019-10-07 |
| Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders (NCT03943537) | Mclean Hospital | 2019-10-01 |
| A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder (NCT04030143) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2019-08-01 |
| Using Neuroplasticity-Based Computerized Training to Improve Emotion Regulation in Bipolar Disorder (BRAINS) (NCT05683431) | Rush University Medical Center | 2019-03-22 |
| A Trial of Single- and Multiple-doses of Aripiprazole in Adult Subjects With Schizophrenia or Bipolar I Disorder (NCT03854409) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2019-01-31 |
| Multicenter, Randomized, Comparative and Prospective Study Evaluating the Impact on the Care Path of an Editorial Program Accompanied by Advance Directives in Psychiatry (DAP) for People Suffering From Schizophrenia, Bipolar I Disorder or Schizoaffective Disorder (NCT03630822) | Assistance Publique Hopitaux De Marseille | 2019-01-02 |
| Efficacy of Convulsive Therapies for Bipolar Depression (NCT03641300) | Centre for Addiction and Mental Health | 2018-09-21 |
| Continuous Theta Burst Stimulation as an add-on Treatment for Bipolar Depression (NCT03603561) | Universiteit Antwerpen | 2018-08-01 |
| ERG Components in Schizophrenia and Bipolar Disorder Type I (NCT03788811) | diaMentis Inc. | 2018-07-05 |
| A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features (NCT03573297) | AbbVie | 2018-06-15 |
| Low Field Magnetic Stimulation: Imaging Biomarkers in Geriatric Bipolar Depression (NCT03484494) | Mclean Hospital | 2018-05-29 |
| A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder. (NCT03287869) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2017-10-24 |
| Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders (NCT03292848) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2017-10-10 |
| Gabapentin for Bipolar & Cannabis Use Disorders (NCT03334721) | Medical University of South Carolina | 2017-10-01 |
| A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder (NCT03257865) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2017-09-19 |
| A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder (NCT03259555) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2017-09-14 |
| Financial Incentives to Improve Acceptance of Antipsychotic Injections (NCT03192631) | Focus Community Mental Health Team | 2017-07-01 |
| Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 (NCT03201757) | Alkermes, Inc. | 2017-06-15 |
| Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder (NCT03187769) | Alkermes, Inc. | 2017-06-08 |
| The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression. (NCT03156504) | Mayo Clinic | 2017-06-01 |
| LiveWell: A Mobile Intervention for Bipolar Disorder (NCT03088462) | Northwestern University | 2017-03-20 |
| Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System (NCT02722967) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2016-03-01 |
| Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression. (NCT02593643) | Sunnybrook Health Sciences Centre | 2016-01-01 |
| Ginger.io Behavioral Health Study (NCT02491307) | Community Health Center, Inc. | 2015-07-01 |
| Lurasidone and Cognition in Bipolar I Disorder (NCT02147379) | University of British Columbia | 2014-05-01 |
| A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder. (NCT01986114) | Sumitomo Pharma Co., Ltd. | 2014-01-29 |
| Emotional Intelligence in Schizophrenia and Bipolar-I- Disorder (NCT01998516) | Medical University Innsbruck | 2013-12-01 |
| Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents (NCT01731119) | University of North Carolina, Chapel Hill | 2012-12-01 |
| Lifestyle Intervention for Diabetes and Weight Management in Psychosis (NCT01828931) | Centre for Addiction and Mental Health | 2012-12-01 |
| Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients (NCT01567527) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2012-08-01 |
| Creatine Monohydrate as Adjuvant Therapy for Bipolar Depression (NCT01655030) | University of Sao Paulo | 2012-07-01 |
| Potentiation of Quetiapine Treatment With Lithium or Aripiprazole in Bipolar 1 Nonresponders Patients (NCT01710163) | University of Sao Paulo | 2012-06-01 |
| This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296 (NCT01575561) | Sumitomo Pharma America, Inc. | 2012-06-01 |
| Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692) (NCT01395992) | Forest Laboratories | 2012-04-01 |
| An Observational Modified Prescription-event Monitoring Study of Asenapine (Sycrest) (NCT01765127) | Professor Saad Shakir | 2012-01-01 |
| Sequential Multiple Assignment Treatment for Bipolar Disorder (NCT01588457) | The University of Texas Health Science Center at San Antonio | 2011-06-01 |
| Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex (NCT01358357) | Sumitomo Pharma America, Inc. | 2011-06-01 |
| Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder. (NCT00958633) | University of British Columbia | 2010-11-01 |
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1) (NCT01206517) | Organon and Co | 2010-07-18 |
| Emotion Regulation Group Therapy for Bipolar Disorder (NCT01207505) | Massachusetts General Hospital | 2010-07-01 |
| Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder (NCT01059539) | Forest Laboratories | 2010-02-28 |
| Safety and Efficacy of Cariprazine for Bipolar I Disorder (NCT01058668) | Forest Laboratories | 2010-02-01 |
| Study in Adolescents With Schizophrenia or Bipolar Disorder (NCT00982020) | Eli Lilly and Company | 2009-09-01 |
| Efficacy of Combined Treatment for Young Bipolar I Disorder (NCT00976794) | University of Sao Paulo | 2009-01-01 |
| Sensoril(Ashwaganhda)for Bipolar Disorder (NCT00761761) | University of Pittsburgh | 2008-10-01 |
| Reducing Medical Risks in Individuals With Bipolar Disorder - Full Study (NCT00746343) | University of Pittsburgh | 2008-09-01 |
| Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain (NCT00709202) | Nathan Kline Institute for Psychiatric Research | 2008-07-01 |
| Staccato Loxapine in Agitated Patients With Bipolar Disorder (NCT00721955) | Alexza Pharmaceuticals, Inc. | 2008-07-01 |
| Safety and Efficacy of Olanzapine in the Long-term Treatment for Bipolar I Disorder, Depressed (NCT00618748) | Eli Lilly and Company | 2008-02-01 |
| A Multicenter, Investigative Study of the Safety and Efficacy of Extended Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode (NCT00606320) | Otsuka Pharmaceutical Co., Ltd. | 2008-01-01 |
| A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group-comparison Trial of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode (NCT00606281) | Otsuka Pharmaceutical Co., Ltd. | 2008-01-01 |
| A Multicenter Investigative Study of the Safety and Efficacy of Long-term Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode (NCT00606229) | Otsuka Pharmaceutical Co., Ltd. | 2008-01-01 |
| A Multicenter, Placebo-controlled, Double-blind Investigative Extension Trial of the Safety and Efficacy of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode (NCT00606177) | Otsuka Pharmaceutical Co., Ltd. | 2008-01-01 |
| Crossover Bioequivalence Study of Quetiapine Fumarate 25 mg Tablets Under Fed Conditions (NCT01570894) | Roxane Laboratories | 2007-07-01 |
| Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder (NCT00608075) | University of Cincinnati | 2007-04-01 |
| Crossover Bioequivalence Study of Quetiapine Fumarate 300 mg Tablets Under Steady State Fasted Conditions (NCT01570959) | Roxane Laboratories | 2007-04-01 |
| A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients (NCT00402324) | Eli Lilly and Company | 2006-12-01 |
| The Young Adult and Pediatric Bipolar Study (NCT00350857) | Validus Pharmaceuticals | 2006-07-01 |
| Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate in the Recurrence Prevention of Bipolar I Disorder (NCT01825837) | Bial - Portela C S.A. | 2006-03-01 |
| Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder (NCT01824602) | Bial - Portela C S.A. | 2006-02-01 |
| Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Alcohol Dependency in Patients With Bipolar Disorder (NCT00114686) | AstraZeneca | 2006-01-01 |
| Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder (NCT01822678) | Bial - Portela C S.A. | 2005-12-01 |
| A Double-Blind Randomized Placebo Controlled Study of Quetiapine for the Treatment of Depression in Adolescents With Bipolar Disorder (NCT00232414) | University of Cincinnati | 2005-10-01 |
| A Study for the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents (NCT00195780) | Abbott | 2005-02-01 |
| PK Effects of Bifeprunox & Valproate in Bipolar I (NCT00141505) | Solvay Pharmaceuticals | 2005-02-01 |
| An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder. (NCT00228059) | Novartis | 2005-01-01 |
| An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder (NCT00238485) | Novartis | 2005-01-01 |
| L-Carnosine for Bipolar I Disorder (NCT00177463) | University of Pittsburgh | 2004-09-01 |
| Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder (NCT00227305) | AstraZeneca | 2004-08-01 |
| A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode (NCT00094432) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2004-06-01 |
| Efficacy & Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder (NCT00107731) | AstraZeneca | 2004-04-01 |
| Risperdal Consta for Bipolar Disorder (NCT00177164) | University of Pittsburgh | 2003-11-01 |
| Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode (NCT01977300) | University of British Columbia | 2003-01-01 |
| Effects of Comorbid Personality Disorder on the Treatment of Bipolar I Disorder (NCT00178061) | University of Pittsburgh | 1997-08-01 |